News - Appointments

Alligator Bioscience AB has appointed Søren Bregenholt as chief executive, effective 1 June, to lead the Swedish company’s international expansion and business development activities.

Engitix Therapeutics of the UK has made two new appointments to its management team. Alan Holmes joins the company as senior director, fibrosis, and John Prime has been named director, computational biolo

Immunocore Plc, a UK company developing T cell receptor bispecific immunotherapies, has announced two new appointments.

Michael J Parini has been appointed to the newly-created role of president and chief operating officer at UK-based Freeline Therapeutics Plc, a developer of gene therapies.

NovalGen Ltd of the UK has announced a number of key appointments to its management team as it prepares to bring its first bispecific antibody therapeutic into human trials.

Tahamtan Ahmadi has been appointed to the newly created position of chief medical officer, head of experimental medicines, at the Danish biotechnology company Genmab A/S.

Sweden-based Hansa Biopharma AB has appointed Magnus Korsgren as head of research and development to advance the company’s pipeline of drug candidates for rare immunologic diseases.

Jeroen Rovers, formerly managing director of DCprime of the Netherlands, has been named chief medical officer at Immunicum AB following the merger of the two companies in December 2020.

Heidelberg Pharma AG has expanded its management team with the appointment of Mathias Locher to the newly created position of chief development officer. Simultaneously, it has promoted András Strassz to the position of chief medical officer.

4D Pharma Plc, which is developing live biotherapeutic products for cancer, has appointed John Beck as chief financial officer and a member of the management team. Live biotherapeutics are a class of drug derived from the microbiome.